Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.

Xia X, Huang C, Liao Y, Liu Y, He J, Guo Z, Jiang L, Wang X, Liu J, Huang H.

J Exp Clin Cancer Res. 2019 May 24;38(1):220. doi: 10.1186/s13046-019-1227-7.

2.

Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination.

Liao Y, Xia X, Liu N, Cai J, Guo Z, Li Y, Jiang L, Dou QP, Tang D, Huang H, Liu J.

Oncogene. 2018 Apr;37(14):1896-1910. doi: 10.1038/s41388-017-0069-z. Epub 2018 Jan 22.

3.

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK.

Mol Cancer Ther. 2017 Jul;16(7):1389-1400. doi: 10.1158/1535-7163.MCT-17-0111. Epub 2017 May 3.

4.

Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor.

Liao Y, Liu N, Hua X, Cai J, Xia X, Wang X, Huang H, Liu J.

Cell Death Dis. 2017 Feb 2;8(2):e2585. doi: 10.1038/cddis.2016.477.

5.

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD.

Mol Pharmacol. 2015 Jun;87(6):1006-12. doi: 10.1124/mol.114.097477. Epub 2015 Mar 31.

6.

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK.

Breast Cancer Res. 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599.

7.

Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.

Kawahara T, Ide H, Kashiwagi E, El-Shishtawy KA, Li Y, Reis LO, Zheng Y, Miyamoto H.

Urol Oncol. 2016 Oct;34(10):432.e15-23. doi: 10.1016/j.urolonc.2016.05.016. Epub 2016 Jun 18.

PMID:
27330033
8.

Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.

Anestis A, Sarantis P, Theocharis S, Zoi I, Tryfonopoulos D, Korogiannos A, Koumarianou A, Xingi E, Thomaidou D, Kontos M, Papavassiliou AG, Karamouzis MV.

J Cancer Res Clin Oncol. 2019 May;145(5):1221-1233. doi: 10.1007/s00432-019-02872-9. Epub 2019 Feb 25.

PMID:
30805773
9.

Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.

Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC.

Prostate. 2015 Sep;75(13):1341-53. doi: 10.1002/pros.23015. Epub 2015 May 13.

10.

Non-canonical AR activity facilitates endocrine resistance in breast cancer.

Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E.

Endocr Relat Cancer. 2019 Feb 1;26(2):251-264. doi: 10.1530/ERC-18-0333.

PMID:
30557851
11.

IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-α Signaling.

Pilling AB, Hwang O, Boudreault A, Laurent A, Hwang C.

Prostate. 2017 Jun;77(8):866-877. doi: 10.1002/pros.23327. Epub 2017 Feb 27.

PMID:
28240376
12.

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.

Clin Cancer Res. 2014 Jun 15;20(12):3198-3210. doi: 10.1158/1078-0432.CCR-13-3296. Epub 2014 Apr 16. Erratum in: Clin Cancer Res. 2017 Jan 1;23 (1):323.

13.

The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells.

Abazid A, Martin B, Choinowski A, McNeill RV, Brandenburg LO, Ziegler P, Zimmermann U, Burchardt M, Erb H, Stope MB.

J Cell Biochem. 2019 Jul 11. doi: 10.1002/jcb.28929. [Epub ahead of print]

PMID:
31297844
14.

Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.

Shiota M, Yokomizo A, Takeuchi A, Itsumi M, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

Prostate. 2014 Jun;74(9):959-69. doi: 10.1002/pros.22813. Epub 2014 Apr 17.

PMID:
24740858
15.

Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.

Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D.

Oncotarget. 2015 Dec 8;6(39):41976-87. doi: 10.18632/oncotarget.5659.

16.

Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.

Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, Zoubeidi A.

Eur Urol. 2015 Jun;67(6):986-990. doi: 10.1016/j.eururo.2014.08.006. Epub 2014 Aug 20.

PMID:
25151012
17.

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.

Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ.

Oncotarget. 2016 Jun 28;7(26):40690-40703. doi: 10.18632/oncotarget.9816.

18.

Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.

Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O'Donovan N, Crown J, Duffy MJ.

Endocr Relat Cancer. 2016 Apr;23(4):323-34. doi: 10.1530/ERC-16-0068. Epub 2016 Mar 1.

PMID:
26932782
19.

Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.

Zhang Z, Cheng L, Li J, Farah E, Atallah NM, Pascuzzi PE, Gupta S, Liu X.

Cancer Res. 2018 Jun 15;78(12):3147-3162. doi: 10.1158/0008-5472.CAN-17-3006. Epub 2018 Apr 26.

20.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674. Epub 2013 Jun 13.

PMID:
23765603

Supplemental Content

Support Center